zaleplon (sonata) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Zaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zaleplon also binds selectively to the CNS GABAA-receptor chloride ionophore complex at benzodiazepine(BZ) omega-1 (BZ1, ο1) receptors. Zaleplon exerts its action through subunit modulation of the GABABZ receptor chloride channel macromolecular complex. Zaleplon also binds selectively to the brain omega-1 receptor located on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding. Zaleplon is marketed under the brand names Sonata, Starnoc, and Andante.   NCATS

Chemistry

  • SMILES: CCN(C(C)=O)C1=CC(=CC=C1)C2=CC=NC3=C(C=NN23)C#N
  • InChIKey: HUNXMJYCHXQEGX-UHFFFAOYSA-N
  • Mol. Mass: 305.3339
  • ALogP: 2.64
  • ChEMBL Molecule:
    zaleplon  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1748 - $0.1789
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3'-(3-cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-n-ethylacetanilide | 3'-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)-n-ethylacetanilide | acetamide, n-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-n-ethyl- | cl 284846 | cl 284,846 | cl-284846 | cl284,846 | l846 | l 846 | l-846 | ljc 10846 | ljc-10846 | n-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-n-ethylacetamide | skp-1041 | sonata | starnoc | zal-846 | zaleplon | zelepion

Organizations (29)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (1)


 

Sleep Initiation and Maintenance Disorders (approved 1999)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Anxiety Disorders (Phase 3)

Dementia (Phase 3)

Depression (Phase 3)

Healthy Volunteers (Phase 1)

HIV Infections (Phase 2)

Memory (Phase 4)

Psychophysiologic Disorders (Phase 3)

Schizophrenia (Phase 3)

Sleep (Phase 4)

Sleep Initiation and Maintenance Disorders (Phase 2)

Sleep Wake Disorders (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue